HZNP News 14.18 05/01/2014 05:06:32 Horizon Pharma Inc (HZNP

New Post Public Reply Private Reply Replies (0) Message Board

May 1, 2014 at 6:06 AM

Horizon Pharma Inc (HZNP) 14.18 $HZNP

Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co
PR Newswire - Wed Apr 30, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.

Horizon Pharma to Host Conference Call and Webcast to Discuss First Quarter 2014 Financial Results on May 9, 2014
Marketwire - Fri Apr 25, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its first quarter 2014 financial results will be released on Friday, May 9, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.

Horizon Pharma awards inducement grants in accordance with NASDAQ Listing Rule 5635(c)(4)
M2 - Thu Apr 24, 5:03AM CDT
Pharmaceutical company Horizon Pharma (NASDAQ:HZNP) on Wednesday granted stock options to ten new non-executive employees to purchase up to 76,500 shares of its common stock.

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marketwire - Wed Apr 23, 3:35PM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that on April 23, 2014 the Compensation Committee of its Board of Directors granted inducement awards to 10 new employees.

Technical Report on Top Gainers -- Research on Centene, Prana Biotechnology, Horizon Pharma, and Scientific Games
PR Newswire - Wed Apr 23, 10:34AM CDT
On Tuesday, April 22, 2014, the NASDAQ Composite ended at 4,161.46, up 0.97%, the Dow Jones Industrial Average finished the session 0.40% higher at 16,514.37, and the S&P 500 closed at 1,879.55, up 0.41%. The gains were broad based as eight out of ten sectors finished on a higher note. A number of stocks saw large movements, including Centene Corp. (NYSE: CNC), Prana Biotechnology Ltd (NASDAQ: PRAN), Horizon Pharma Inc. (NASDAQ: HZNP) and Scientific Games Corp. (NASDAQ: SGMS). Free technical research on CNC, PRAN, HZNP and SGMS can be downloaded upon signing up at:

Is A Short Squeeze Ahead for Horizon Pharma (HZNP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 7:41AM CDT
Is A Short Squeeze Ahead for Horizon Pharma (HZNP)?

Horizon Pharma elects H Thomas Watkins to board
M2 - Fri Apr 18, 6:53AM CDT
Pharmaceutical company Horizon Pharma (NasdaqGS:HZNP) revealed on Thursday the addition of H Thomas Watkins to its board of directors.

Horizon Pharma Announces the Appointment of H. Thomas Watkins to Its Board of Directors
Marketwire - Thu Apr 17, 6:31AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of H. Thomas Watkins, former director, president and chief executive officer of Human Genome Sciences, to its board of directors. Additionally, Jean-Francois Formela, M.D. has resigned from the Horizon board of directors.

Horizon Pharma Announces Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Vidara Therapeutics International Ltd.
Marketwire - Wed Apr 16, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. ("Vidara"

. The waiting period was scheduled to expire on May 1, 2014. Completion of the transaction remains subject to approval by Horizon's stockholders and other customary closing conditions.

Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Horizon Pharma announces Notice of Allowance for US Patent Application for RAYOS for treating a broad range of diseases
M2 - Fri Apr 11, 4:56AM CDT
Specialist pharmaceutical company Horizon Pharma (NASDAQ:HZNP) revealed on Thursday the receipt of Notice of Allowance for US Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers its US approved product RAYOS.

Horizon Pharma (HZNP): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:33AM CDT
Horizon Pharma looks well positioned for a solid gain, but has been overlooked by investors lately. This Generic Drugs stock has actually seen estimates rise over the past month for the current fiscal year. This year’s expected earnings growth over the prior year is 147.1%, which should ultimately translate into price appreciation.

Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets
Marketwire - Thu Apr 10, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS(R).

Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 03, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Technical Data on Top Gainers -- Research on JinkoSolar, Horizon Pharma, YY Inc., and Questcor Pharma
PR Newswire - Wed Apr 02, 8:59AM CDT
On Tuesday, April 01, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including JinkoSolar Holding Co. Ltd (NYSE: JKS), Horizon Pharma Inc. (NASDAQ: HZNP), YY Inc. (NASDAQ: YY) and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). Free technical research on JKS, HZNP, YY and QCOR can be downloaded upon signing up at:

Biotechs Giving Uncle Sam the Shaft
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 5:08PM CDT
As they say in real estate: location, location, location. Biotechs have been acquiring companies in large part for their address. Specifically, they're buying so they can move to places like Ireland, where taxes are substantially lower than in the...

Horizon Pharma grants inducement stock options to 26 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 28, 4:55AM CDT
Pharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that it has awarded inducement stock options to purchase an aggregate of 96,750 shares of its common stock to 26 new employees.

Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:47AM CDT
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on HZNP’s earnings for the coming quarter and year.

Acquisitions, Appointments, and New Product Developments - Analyst Notes on Boston Scientific, Horizon Pharma, Alkermes, Agilent, and BD
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), Horizon Pharma Inc. (NASDAQ: HZNP), Alkermes Plc (NASDAQ: ALKS), Agilent Technologies Inc. (NYSE: A), and Becton, Dickinson and Co. (NYSE: BDX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RadianX Grabs $9M for Perovskite Solar Push

By Evelyn Baker Updated Nov 5, 2026 Category News Views 105

RadianX Making Waves with New Funding Diving headfirst into the clean energy scene, RadianX has snagged a hefty $9 million in fresh funding. Now, this isn't some chump change. We're talking about a solid push to get their perovskite photovoltaic modules off the ground and into widespread use. They've got financial backing from big players like SOSV and Twynam, spearheaded...

Coinhub Funded's Bold Move in Trading World

A New Name in the Trading Game Right out of Charlestown, Saint Kitts and Nevis, Coinhub Funded is making waves in the crypto prop trading world, and boy, they're not pulling any punches. They've just thrown their hat in the ring with a tantalizing offer: get your hands on a funded trading account up to $200K, and if that's not enough to get your pulse racing, they've got...

Rice Sets Course in Houston’s Thriving Innovation Hub

Houston's Innovation Scene Expands The ground's barely settled and already Rice University is shaking up the scene in Houston’s Ion District with the Arc. At nearly 200,000 square feet, this powerhouse is set to bridge the gap between research, industry, and entrepreneurs, pushing ideas from discovery to reality. A Groundbreaking Investment For anyone with half an idea...

PJM Prepares to Tackle Winter Power Demands

Eyeing the Season Ahead The chill in the air isn't just meteorological; there's a business note to notice every winter in PJM's sprawling territory. With power supplies robust yet stretched thin, PJM is bracing to navigate another demanding cold season. They’ve announced they have 182,426 MW of operational capacity nipping at the heels of a projected peak demand of...

Elanco Surges with Solid Q3, Raises 2026 Forecast

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Gerstle Snelson Grabs Top Ranks in 2027 Best Law Firms

Big Wins on the Legal Stage When it comes down to the concrete jungle of construction law, Gerstle Snelson, LLP isn't just laying bricks; they're building skyscrapers. This Texas-based firm has secured three Regional Tier 1 rankings in the 2027 Best Law Firms® list. That's enough to make any law outfit puff out its chest a bit. What's in the Rankings? These rankings...

UN's AI Toolbox Aims to Keep City Oversight Human

Artificial Intelligence: Tool or Tyrant? Ever feel like we're on a runaway train with this AI business in city management? The United Nations seems to think so, and it’s stepping in with a big red STOP sign—or rather, a toolbox. This week, in a grand procession at Barcelona's Smart City Expo, they rolled out the United for Smart Sustainable Cities (U4SSC) Toolbox,...

Segway Powersports Pushes Deeper Into European Markets

Riding the Waves of European Market Expansion Segway Powersports, the adrenaline junkie's friend in motorsports, is cranking up its presence in Europe. Fresh off their annual International Business Partner Conference at EICMA 2026 in Milan, they’re not just talking shop. They've got a whole plan set to muscle in deeper into the European market with a new lineup for...

TDS Hits Bumps but Keeps Shareholders Happy

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

SM Investments Wins Five Golden Arrows: Governance on Point

Gold Arrows and Golden Standards What’s in a bunch of gold arrows, you might ask? Well, for SM Investments Corporation, those Five Golden Arrows from the Institute of Corporate Directors aren't just shiny trinkets. They're badges of honor, symbols of a rock-solid governance fortress. For the third year running, they’ve nailed the top spot under the corporate...